Fredun Pharmaceuticals Q1 FY27: profit up 64% on income rise

Overview of the update

Fredun Pharmaceuticals Limited reported a strong first-quarter performance, with year-on-year growth in profit and operating metrics for the quarter ended June 2025. The update also included corporate developments such as board appointments and a credit rating upgrade. Market data in the same update shows the stock is listed on BSE and is not traded on NSE. Price and market-cap figures were presented from different snapshots, including a price of ₹2,311 with market cap near ₹1.3K crore, and another snapshot showing price ₹1,624 with market cap ₹872 crore. The stock was also shown trading at a P/E of 38.3 with market cap ₹1,305 crore in one of the data points. These figures indicate the stock has been actively tracked, but they should be read as point-in-time references. The core financial numbers, however, clearly show higher year-on-year profitability in Q1.

Q1 FY27 performance: income, EBITDA and profit

For Q1, total income was reported at ₹119.86 crore compared with ₹78.81 crore in the corresponding quarter last year, a year-on-year increase of 52.08%. Net profit for the quarter rose to ₹6.77 crore from ₹4.13 crore, up 63.82% year-on-year. EBITDA was reported at ₹16.99 crore versus ₹10.48 crore, reflecting 62.15% growth. The EBITDA margin improved to 14.18% from 13.30%, an expansion of 88 basis points. Net profit margin was reported at 5.64% compared with 5.24%, an improvement of 40 basis points. Diluted EPS was cited at ₹14.33 in the highlights table, up from ₹8.79. The same update also contained a quarterly table showing “Diluted Normalized EPS” of 4.78 for June 2025 and 3.05 for March 2026, which readers should treat as a separate reporting line item.

QoQ movement: revenue softness and lower expenses

The quarterly comparison table (QoQ basis) showed total revenue of ₹119.85 crore in June 2025 versus ₹209.40 crore in March 2026, indicating a sequential decline of 27.34%. Total operating expense declined to ₹104.28 crore from ₹186.73 crore, down 31.39% QoQ. Operating income was reported at ₹15.57 crore versus ₹22.66 crore in March 2026, and net income at ₹6.77 crore versus ₹6.53 crore. Depreciation and amortisation stood at ₹1.42 crore, compared with ₹2.82 crore in the prior quarter. Selling, general and administrative expenses were reported at ₹7.63 crore versus ₹9.01 crore. The company also reported net income before taxes of ₹9.04 crore for the quarter.

Key quarterly numbers at a glance

FY26 audited outcome: profit up, dividend and bonus issue

In a separate FY26 audited results update referenced alongside the quarterly numbers, Fredun Pharmaceuticals reported standalone net profit of ₹33.21 crore, up 59.59% from the previous year. Total income from operations rose 40.08% to ₹639.12 crore. The board recommended a final dividend of ₹0.70 per share and approved a 2:1 bonus issue. The company also approved an increase in authorised share capital to ₹50 crore as part of the same set of decisions. Separately, another corporate action line noted a dividend of ₹0.70 declared on 23 September 2025. These developments matter for shareholders because they directly affect share count, payout expectations, and capital structure disclosures.

Balance sheet and cash flow signals (FY24 to FY26)

The income statement data in the update (presented in INR millions) implies steady scaling over the last three years. FY26 revenue was listed at 6,354.657 million, which converts to ₹635.47 crore, versus ₹453.82 crore in FY25 and ₹346.58 crore in FY24. FY26 net income was listed at 332.07 million, or ₹33.21 crore, versus ₹19.74 crore in FY25 and ₹15.62 crore in FY24. Total assets were reported at 6,420.823 million, or ₹642.08 crore, in FY26. Cash from operating activities was reported at 1,152.545 million, or ₹115.25 crore, in FY26, compared with negative ₹29.06 crore in FY25. Investing cash flow was negative at 735.908 million, or ₹73.59 crore, while financing cash flow items were negative at 379.109 million, or ₹37.91 crore.

Corporate developments: directors, credit rating and order book

Along with the Q1 performance update, the company announced the appointment of two new independent directors, Mr. Anshu Agarwal and Ms. Sonal Desai, for five-year terms. The update also stated the company received a credit rating upgrade to IVR BBB/Stable from IVR BBB-/Stable for facilities totaling ₹139.64 crore. Fredun Pharmaceuticals also cited an order book exceeding ₹200 crore. Such disclosures are typically watched for their implications on governance standards, borrowing costs, and near-term execution visibility. A separate line indicated the company filed a Q4 FY26 compliance certificate with BSE on April 6, 2026, covering the quarter ended March 31, 2026. The same update also referred to an earnings conference call scheduled for August 1, 2025, linked to Q1 results.

Stock snapshot: price levels, returns and NSE availability

The market section in the update carried multiple point-in-time trading references. One snapshot showed price at ₹2,311 and market cap near ₹1.3K crore, and another listed price ₹1,624 with market cap ₹872 crore. The stock was also described as trading at a P/E of 38.3 with market cap ₹1,305 crore. The update stated the stock is not traded on NSE. Reported returns included 1D +0.57%, 1M +13.48%, 6M +34.18%, 1Y +224.60%, and 5Y +465.52%. Another line stated the shares closed at ₹2,384.10 on May 25, 2026 (BSE) and delivered 33.41% over six months and 222.74% over 12 months.

Other operational and tracking metrics flagged

The update also flagged two monitoring points: promoter holding decreased by 5.87% over the last quarter, and debtor days increased from 85.2 to 142 days. Both metrics can influence investor interpretation of cash conversion and ownership stability, even when reported profitability is rising. The quarterly peer-style table included details such as interest cost, tax, and reported PAT for multiple quarters, showing reported PAT of ₹6.77 crore in June 2025 and ₹7.07 crore in March 2025 within that dataset. It also provided quarter-by-quarter line items such as EBITDA, depreciation, and EBT, which help reconcile operating performance with finance costs. Separately, the company’s stated target for topline growth was cited as 25% to 30% annually for FY27 and the next few years. That target is a company statement and should be read as an aim rather than an outcome.

What to watch next

The update included a reference to an “upcoming earnings date” of 25 May 2026, while also listing the last earnings date as Q4 FY25-26 on 25 May 2026, indicating the date was used as a marker in the dataset. Investors will typically watch for the next formal results release and any further filings related to the dividend, bonus issue, and authorised capital increase. On operations, order book execution and working-capital movement will remain key, especially given the increase in debtor days highlighted in the same update. Governance changes, including the appointment of new independent directors, may also lead to additional disclosures in subsequent filings. For the stock, the mix of reported price and market-cap snapshots suggests investors should verify the latest BSE quote at the time of decision-making. The most concrete near-term anchors remain the reported Q1 income and profit numbers and the audited FY26 profit and income from operations.